Abstracts

Notes From The Field: Implementing PrEP in Resource-Constrained Settings

Background: Unequivocal evidence from landmark clinical trials has demonstrated that oral tenofovir disoproxil fumarate-based Pre-Exposure Prophylaxis (PrEP) is a highly effective biomedical intervention for preventing acquisition of HIV-1 infection. For the first time we have a much sought HIV prevention tool for vulnerable HIV-uninfected individuals without requiring negotiation of safe sex with partners. We currently…

A Community Perspective on PrEP

Background: Following the success of several clinical pre-exposure prophylaxis (PrEP) trials and the approval of FTC/TDF for the prevention of HIV, attention has shifted to the interest and uptake of PrEP as well as the best practices for PrEP implementation. In the United States, young men who have sex with men (YMSM), particularly racial minority…

Choosing Populations for Maximal Impact

Background: Oral emtricitabine/tenofovir (FTC/TDF)-based pre-exposure prophylaxis (PrEP) has been shown to prevent acquisition of HIV. PrEP is a promising, yet resource-intensive prevention strategy with high drug and monitoring costs. Providers and policy makers need evidence-based guidance to make decision on prioritizing populations for PrEP. This talk will discuss development of optimal strategies for identifying subgroups…

Transmission Clusters Recent Infection and STIs Among*New HIV Cases: Implications for Prevention

Background: Only HIV transmission that is occurring in the present can be interrupted. Recent infection, a new diagnosis of a sexually transmitted infection (STI) and phylogenetically-linked transmission clusters are factors that may help direct prevention efforts towards current chains of HIV transmission. We therefore examined correlates associated with recent and longer-standing infection among persons newly-diagnosed…

Correlating GSK1265744 Plasma Levels to Prevention of Rectal SHIV Transmission in Macaques

Background: GSK1265744 (GSK744) is an InSTI with properties permitting formulation as a long-acting (LA) injectable nanoparticle suspension (200 mg/mL). We reported at CROI 2013 that GSK744LA is effective as PrEP against repeated low-dose intrarectal (IR) SHIV exposures in 8 male rhesus macaques (RM). This follow-up study was performed to confirm our initial findings and determine…

Monthly GSK744 Long-Acting Injections Protect Macaques Against Repeated Vaginal SHIV Exposures

Background: Pre-exposure prophylaxis (PrEP) with long-acting antiretroviral drugs has the potential to overcome the challenges of adherence associated with daily PrEP. The HIV integrase inhibitor GSK1265744 has been formulated as a long-acting injectable nanosuspension (GSK744 LA) and is an attractive candidate for PrEP. We used a pigtail macaque model to investigate systemic and vaginal GSK744…

Safety and Pharmacokinetics/Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings

Background: Vaginal rings offer sustained multi-drug delivery for pre-exposure prophylaxis of HIV infection. A dapivirine (DPV) vaginal ring, an NNRTI, is in Phase III trials. Maraviroc (MVC), a CCR5 co-receptor antagonist, is approved for oral HIV treatment but has not been studied intravaginally. This trial evaluated the safety and pharmacokinetic/pharmacodynamics of vaginal rings containing DPV…

FAME-02: A Phase I Trial to Assess Safety PK and PD of Gel*and Film Formulations of Dapivirine

Background: Film formulations of topical microbicides have theoretical advantages over gels and intravaginal rings. Relying on physiologic fluids to dissolve, the product may provide more efficient drug delivery while minimizing disruption of innate immune defenses, product application may ensure privacy while avoiding leakage, and the cost associated with scale up of vaginal films compares favorably…